<DOC>
	<DOCNO>NCT00782067</DOCNO>
	<brief_summary>This study investigate drug midostaurin take orally twice daily effective safe treat patient aggressive systemic mastocytosis mast cell leukemia without additional hematological neoplasm .</brief_summary>
	<brief_title>Efficacy Safety Midostaurin Patients With Aggressive Systemic Mastocytosis Mast Cell Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Key Confirmed diagnosis aggressive systemic mastocytosis ( ASM ) mast cell leukemia ( MCL ) accord WHO criteria SM establish criterion ASM MCL ( Valent et al 2003 ) , present least one measurable CFinding . ECOG performance status 03 Life expectancy &gt; 12 week ECG : QTc interval ≤ 450 m Meeting follow laboratory value : AST ALT must ≤ 5 x Upper Limit Normal ( ULN ) elevation solely due ASM/MCL , otherwise AST , ALT must ≤ 2.5 x ULN Serum Bilirubin must ≤ 3 x Upper Limit Normal ( ULN ) elevation solely due ASM/MCL , otherwise serum bilirubin must 1.5 x ULN Serum Creatinine ≤ 2.0 mg/dL Key Any concurrent severe know disease ( except carcinoma insitu ) concurrent severe and/or uncontrolled medical condition include congestive heart failure grade III IV accord NYHA classification ejection fraction &lt; 50 % , etc . Patients pulmonary infiltrate include suspect infectious origin . Exception : Patients pleural effusion relate disease study confirm investigator permit enter study Patients demonstrate relapse 3 prior regimen SM treatment ( include give supportive care ) Patients receive investigational agent , chemotherapy , interferonα , 2chlorodeoxyadenosine ( 2CdA , cladribine ) within 30 day prior first dose Patients ASM eosinophilia know positivity FIP1L1PDGFRα fusion unless demonstrate relapse disease progression prior imatinib therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Aggressive systemic mastocytosis</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>C-Findings</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>KIT mutation</keyword>
	<keyword>AHNMD</keyword>
	<keyword>Systemic</keyword>
	<keyword>Aggressive</keyword>
</DOC>